Anxiety & Stress Disorders

The results suggest that the bacterium Lactobacillus may aid in the management of stress and in the prevention of these disorders.

From late-life treatment-resistant depression to the mental health benefits of gratitude, here are highlights from the week in Psychiatric Times.

What is new in research on anxiety symptoms and disorders?

Ketamine for anxiety? Researchers performed a systematic review and meta-analysis of ketamine’s anxiolytic effects.

Children have real worries driven by real threats when it comes to climate change.

"During the past 5 years has gabapentin retained its position as one of the top 10 drugs prescribed in the United States."

One reader believes psychiatrists and mental health clinicians should approach climate change with skepticism.

From sleep and neuroendocrine function following TBI to new phase 3 results from a clinical trial evaluating a promising new schizophrenia treatment, here are highlights from the week in Psychiatric Times.

Just because a patient has anxiety or past trauma does not mean they cannot enjoy this spooky holiday…

Social anxiety disorder: an underappreciated and misunderstood condition.

What is new in research on sleep?

What is new in research on psychiatric care for Latinx patient populations?

What is new in research on transcranial magnetic stimulation?

From TMS as a treatment for long COVID to an update on 988 and crisis care, here are highlights from the week in Psychiatric Times.

Fasedienol meets trial endpoints by reducing anxiety during public speaking simulations in patients with social anxiety disorder.

Black mothers in the US experience far worse outcomes. Here’s what clinicians need to know.

This book asks us to reexamine anxiety…

Here’s everything you need to know to about how to integrate apps into your clinical practice.

From research updates on at-home ketamine use to the effects of comorbid depression and anxiety on insomnia treatment, here are highlights from the week in Psychiatric Times.

New research finds depressive and anxiety symptoms impact effectiveness of cognitive behavioral therapy for insomnia.

1 in 5 respondents reported using psychedelic drugs for the purpose of self-treating anxiety, depression, or other mental illnesses.

PME affects many women, yet it remains under-recognized in clinical practice and in research.

Metabolic mediators of anxious depression? Researchers investigated metabolic correlates of overweight/obesity in patients with MDD.

Researchers used an observational cohort study to investigate a potential causal association.

Ketamine is relatively new to the average American. What can you share with them as a mental health clinician?